Diarrhea Clinical Trial
Official title:
A Single-center, Double-blind, Randomized, Placebo-controlled, Two Period / Two Treatment Cross-over Study to Assess the Effect of Florastor® (Saccharomyces Boulardii Lyo) on Gastrointestinal Tolerability, Safety, and Pharmacokinetics of Zavesca® (Miglustat) in Healthy Subjects
Verified date | March 2015 |
Source | Actelion |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review CommitteeCanada: Health Canada |
Study type | Interventional |
Cross-over, tolerability study with healthy subjects taking Zavesca in combination with Florastor. Forty-two subjects will be randomized to one of two treatment sequences of Zavesca with Florastor and Zavesca with Placebo of Florastor. Gastrointestinal tolerability and PK endpoints, demographic, laboratory and safety testing, and AEs and SAEs will be collected throughout the seventy-four day study.
Status | Completed |
Enrollment | 42 |
Est. completion date | August 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Signed informed consent prior to any study-mandated procedure - Healthy male and female subjects aged between 18 and 55 years (inclusive) at Screening - Women must have a negative serum pregnancy test at Screening and negative urine pregnancy test at the first day of each treatment period and must use a reliable method of contraception from Screening during the entire study and up to 30 days after the last dose. Male subjects must agree to use reliable contraception throughout the study and for 4 months after study drug discontinuation - Reliable methods of contraception for all subjects include the following: - Barrier type devices (e.g., male and female condom, diaphragm and contraceptive sponges) used ONLY in combination with a spermicide - Intrauterine devices - Oral contraceptive agent - Depo-Provera (medroxyprogesterone acetate) - Levonorgestrel implants - Abstinence, the rhythm method, and contraception by the partner alone are NOT reliable methods of contraception - A BMI of 18.5 to 30 kg/m2 (inclusive) at Screening - No clinically significant findings on the physical examination, laboratory assessment, electrocardiogram (ECG), and vital signs at Screening Exclusion Criteria: - Ingestion of any medication within 7 days prior to study enrollment (Day 1) except contraceptives - Use of anti-diarrheal medications within 30 days prior to study enrollment (e.g., loperamide) - Use of oral probiotic supplements or S. boulardii within 30 days prior to study enrollment - Use of oral antifungals or antibiotics within 8 weeks prior to study enrollment - History of yeast allergy - Current alcohol or drug dependence - Renal function impairment, (i.e., creatinine clearance [C Cr]<70 mL/min/1.73m2 as per Cockroft-Gault) - History of GI distress including diarrhea (more than 2 loose stools per day, for 5 or more days) within 30 days prior to study enrollment - History of irritable bowel syndrome, inflammatory bowel disease, or other disease resulting in frequent or severe diarrhea - Lactose intolerance - Subjects on any specialized diet, including low carbohydrate diets Lactating, pregnant women or women who plan to become pregnant during the course of the study - History of any neurological disease/symptom, e.g., convulsion - Loss of 500 mL or more of blood within 3 months prior to Screening - Positive results to HIV Ag/Ab, HBsAg or anti-HCV tests - Positive results from the HIV serology at Screening - History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to Screening - Excessive caffeine consumption, defined as >=5 cups of coffee a day or 800mg/day at Screening - Smoking within 3 months prior to Screening and inability to refrain from smoking during the course of the study - Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol - Legal incapacity or limited legal capacity at Screening - Unplanned weight loss defined as >5% within the past month or >=10% during the last 6 months |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | BioPharma Services Inc. | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Actelion |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | PHARMACOKINETIC ENDPOINTS | Plasma PK parameters will be derived by non-compartmental analysis of the concentration-time profiles of miglustat following the last dose at end of Periods 1 and 2. The area under the plasma concentration-time curve during a dosing interval (AUCt). The maximum plasma concentration (Cmax). The time to reach maximum plasma concentration (tmax). | day 16 and day 44 | No |
Other | GENERAL TOLERABILITY/SAFETY ENDPOINTS, OTHER THAN GASTRO-INTESTINAL EVENTS | Treatment-emergent adverse events (TEAEs) up to 48 hours after the last study drug dose in each treatment period. Leading to the premature discontinuation of study drug. Treatment-emergent SAEs up to 48 hours after the last study drug dose in each treatment period. Change from baseline to EOT in body weight and vital signs blood pressure (BP) and heart rate (HR). | baseline to end of study (day 74) | Yes |
Primary | GASTROINTESTINAL TOLERABILITY ENDPOINTS | Total number of days of diarrhea defined as 3 or more loose stools within a 24-hour period (WHO criteria) that meet the criteria of Bristol Stool Score 6-7. | baseline to end of study (day 74) | Yes |
Secondary | GASTROINTESTINAL TOLERABILITY ENDPOINTS | Number of consecutive days of diarrhea defined as 3 or more loose stools (WHO criteria) within consecutive 24-hour periods that meet the criteria of Bristol Stool Score of 6-7. | baseline to end of study (day 74) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06283784 -
Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics In The Prophylaxis Of Diarrhea In Adult Patients
|
N/A | |
Recruiting |
NCT03851835 -
Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis
|
Phase 3 | |
Completed |
NCT04003181 -
The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon
|
N/A | |
Completed |
NCT03596827 -
The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection
|
N/A | |
Recruiting |
NCT05372068 -
Cement flooRs AnD chiLd hEalth (CRADLE)
|
N/A | |
Completed |
NCT03972618 -
Evaluation of the Efficacy of Sawyer Point One Filters in Schools and Homes in the Dominican Republic
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT05052489 -
Registry and Clinical Observation of Children With Diarrhoeal Disease
|
||
Completed |
NCT02428647 -
Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation
|
N/A | |
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT01968408 -
Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children
|
Phase 3 | |
Completed |
NCT01739231 -
Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults
|
Phase 1/Phase 2 | |
Terminated |
NCT01048567 -
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
|
Phase 2 | |
Completed |
NCT01438645 -
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
|
N/A | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Terminated |
NCT01472211 -
Water-based Zinc Intervention Trial in Zinc Deficient Children
|
Phase 0 | |
Not yet recruiting |
NCT01382199 -
Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
|
Phase 3 | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT00760851 -
Yogurt Study in Children 2-4 Years Old Attending Daycare
|
Phase 3 |